CRBN-based selective IKZF1/3 degrader
oral efficacy in lenalidomide-resist. xenograft
from phenotypic screen and optimization
J. Med. Chem., Mar. 4, 2020
Celgene, San Diego, CA
CC-92480 (Celgene/Bristol Myers Squibb (BMS) oral in vivo CRBN-based selective IKZF1/3 degrader)